PHILADELPHIA, May 18 (Reuters) - Bidders emerged for allergy-testing company Phadia AB and test-maker Gen-Probe Inc (GPRO.O), according to The Wall Street Journal.
Laboratory equipment company Thermo Fisher Scientific Inc (TMO.N) is a leading contender for privately owned Phadia, and is involved in the auction for Gen-Probe, the newspaper reported in its online edition.
Phadia could fetch as much as $3 billion in a sale, while Gen-Probe has a market capitalization of $3.8 billion.
Other bidders for Gen-Probe include Novartis AG NOVN.VX, and Life Technologies Corp (LIFE.O), the newspaper said.
The companies could not be immediately reached for comment. (Reporting by Jessica Hall. Editing by Robert MacMillan) (For more M&A news and our DealZone blog, go to here)